Updated: Oct 13, 2008
Actinomyces israelii species is a gram-positive, cast-forming, non–acid-fast, non–spore-forming anaerobic bacillus that is difficult to isolate and identify. Its filamentous growth and mycelialike colonies have a striking resemblance to fungi. They are soil organisms, often found in decaying organic matter (eg, wet hay, straw). It is primarily a commensal microbe found in normal oral cavities, in tonsillar crypts, in dental plaques, and in carious teeth.3,4,5,6
Most reported cases of Actinomyces keratitis (keratoactinomycosis) are caused by A israelii. It is characterized by a dry ulceration with central necrosis, surrounded by a gutter of demarcation, usually accompanied by iritis and hypopyon. In severe cases, descemetocele and perforation may occur.
A primary corneal ulcer attributable to Actinomyces species is rare and usually follows corneal trauma.7 A rare case of keratoactinomycosis developing in the absence of any known ocular trauma was reported in Kuala Lumpur.
See related CME at Update on Contact Lens-Related Microbial Keratitis.
Primary chronic canaliculitis is an uncommon problem caused by A israelii (Streptothrix).
McKellar presented a 10-year-old girl with a 6-month history of intermittent conjunctivitis and discharge from her pouted left lower punctum. Topical treatment with chloramphenicol/polymyxin sulphate failed despite a diagnosis of probable A israelii infection confirmed by microbiology. Surgical exploration revealed a canalicular diverticulum and 3 canaliculiths demonstrating solid casts of Actinomycetes on histologic examination. A therapeutic triad of punctoplasty, cast removal, and adjunctive topical cefazolin resulted in resolution.8,9,10,11,12,13,14,15,16,17,18,19
Actinomycetes have been described as causative organisms in conjunctivitis, blepharitis, dacryocystitis, postsurgical endophthalmitis, and infected porous orbital implant. Cervico-facial actinomycosis has also been reported.
Endophthalmitis
Acute postoperative endophthalmitis caused by Actinomyces neuii after uncomplicated phacoemulsification with posterior chamber intraocular lens implant in a 58-year-old male has been reported. On postoperative day 6, he presented with pain, redness, and decreased visual acuity. Chronic endophthalmitis by Actinomyces neuii subspecies anitratus after uneventful phacoemulsification with implantation of a foldable posterior chamber intraocular lens in a 75-year-old man has been reported as well. Four weeks after surgery, anterior chamber and vitreous cellular debris developed in this eye.20
Endophthalmitis, attributable to Actinomyces viscosus, developed in a 78-year-old man after cataract surgery. Postoperative endophthalmitis with this organism is a rare occurrence. Inflammation was characterized by anterior segment and vitreous cellular debris in cases of chronic postoperative endophthalmitis associated with Actinomyces species.21
Endogenous endophthalmitis has been reported with Actinomyces israelii.22
Orbital actinomycosis
Painful ophthalmoplegia resulting from orbital actinomycosis has been reported.23,24,25,26,27
Primary chronic canaliculitis is an uncommon problem that can be overlooked; however, it may account for approximately 2% of all tearing problems. Actinomycosis may form in up to 2% of all lacrimal disease. Its occurrence is probably much less in other areas.
Actinomycosis occurs worldwide, with a likelihood for higher prevalence rates in areas with low socioeconomic status.
No racial predilection exists.
No sexual predisposition exists.
Actinomycosis can affect people of all ages. No age predisposition exists.
| Blepharitis, Adult | Endophthalmitis, Postoperative |
| Cellulitis, Preseptal | Keratitis, Fungal |
| Chalazion | Nasolacrimal Duct, Obstruction |
| Conjunctivitis, Bacterial | Ulcer, Corneal |
| Contact Lens Complications | |
| Dacryocystitis | |
| Endophthalmitis, Fungal |
Propionibacterium propionicus canaliculitis
Candida species canaliculitis
Histologic examination of the canaliculiths demonstrated that they consisted of solid casts of Actinomycetes with typical branching and filamentous structures. The organisms were found by using a Gram stain on the histopathologic preparations and by using a scanning electron microscopy.
Electron microscopic results of an actinomycosis of the lacrimal canaliculus were presented in 1980. The interior of the actinomycotic conglomerate showed no evidence of a cellular defense reaction, but, in the loosely woven outer network of hyphae, a massive granulocytic reaction was observed to be present. After phagocytosis, the structure of the actinomycotic microorganisms within the granulocytes was not significantly damaged. Within the tissue of the lacrimal canaliculus, adjacent to the actinomycotic conglomerate, an increased number of plasma cells were observed to be present; however, no organisms were present.
An external disease and cornea specialist may provide care for the anterior segment.
An oculoplastics consult may be required for eyelid and orbital involvement.
A posterior segment surgeon is necessary for endophthalmitis.
Actinomyces organisms are usually susceptible to penicillins and cephalosporins. Good results have been obtained by subconjunctival penicillin coadministered with systemic iodides. Alternatively, topical sulfacetamide or penicillin can be used.
Empiric antimicrobial therapy must be comprehensive and should cover all likely pathogens in the context of the clinical setting.
Exerts bactericidal action against penicillin-susceptible microorganisms during the stage of active multiplication. Acts by inhibiting biosynthesis of cell wall mucopeptide, rendering the cell wall osmotically unstable. Not active against penicillinase-producing bacteria, which include many strains of staphylococci
Topical: 100,000-333,000 U/mL in topical
Subconjunctival: 0.5-1.0 million U/mL
Intravitreal injection: 2,000 U / 0.1 mL intravitreal injection, and probenecid 0.5 g PO qid (possible retinal toxicity)
Oral: 400,000 U PO qid (rarely used; poor stomach absorption)
IV: 2-6 million U IV q4h and probenecid 0.5 g PO qid
IM: Depends on formulation
Topical: 10,000-20,000 U/mL
IV: 50,000 U/kg/d IV divided bid/tid
Probenecid can increase effects; coadministration of tetracyclines can decrease effects
Documented hypersensitivity
B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
Caution in impaired renal function
First-generation cephalosporin with excellent activity against gram-positive cocci, including penicillinase-producing Staphylococcus aureus, penicillinase-producing Staphylococcus epidermidis, group A beta-hemolytic streptococci (Streptococcus pyogenes), group B streptococci (Streptococcus agalactiae), and Streptococcus pneumoniae. Ineffective against Bacteroides fragilis and only weak activity against gram-negative organisms.
Topical: 133 mg/mL
Subconjunctival: 100 mg/mL
Intravitreal injection: 2.25 mg / 0.1 mL intravitreal injection, and probenecid 0.5 g PO qid
IV/IM: 500-1,000 mg IV/IM q6h
25-100 mg/kg/d IV/IM divided q6-8h depending on severity of infection; not to exceed 6 g/d
Probenecid can increase effects of penicillin; coadministration of tetracyclines can decrease effects of penicillin
Documented hypersensitivity
B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
Prolonged use may result in overgrowth of nonsusceptible organisms; caution in GI disease, particularly colitis
Parasite biochemical pathways are sufficiently different from the human host to allow selective interference by chemotherapeutic agents in relatively small doses.
N-acetyl-substituted derivative; at 30% solution, topical sulfacetamide has pH of 7.4 and has good tissue penetration.
Solution: Instill 1-3 gtt in affected eye q2-3h, while awake, with less frequent administration at night
Ointment: Apply 0.5-inch ribbon into the conjunctival sac 1-4 times/d
<2 months: Not established
>2 months: Administer as in adults
Effects of sulfonylurea hypoglycemic agents, hydantoin anticonvulsants, and oral anticoagulants increase when administered concurrently with sulfacetamide sodium; PABA antagonizes effects of sulfonamides; PABA esters (eg, procaine) may inhibit antibacterial effect of these agents; trimethoprim enhances effects of sulfacetamide
Documented hypersensitivity
C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
Caution in severely dry eye; ointment may retard corneal epithelial healing; if inflammation or pain persists >48 h or becomes aggravated, reevaluate therapy; adverse effects include local irritation, brow ache, blurred vision, transient burning and stinging, and sensitivity reactions (rare cases of Stevens-Johnson syndrome and exfoliative dermatitis have been reported); GI upset and bone marrow depression have been described
Robboy SJ, Vickery AL Jr. Tinctorial and morphologic properties distinguishing actinomycosis and nocardiosis. N Engl J Med. Mar 12 1970;282(11):593-6. [Medline].
Acevedo F, Baudrand R, Letelier LM, et al. Actinomycosis: a great pretender. Case reports of unusual presentations and a review of the literature. Int J Infect Dis. Jul 2008;12(4):358-62. [Medline].
Figdor D, Davies J. Cell surface structures of Actinomyces israelii. Aust Dent J. Apr 1997;42(2):125-8. [Medline].
Holmberg K, Nord CE, Wadström T. Serological studies of Actinomyces israelii by crossed immunoelectrophoresis: taxonomic and diagnostic applications. Infect Immun. Aug 1975;12(2):398-403. [Medline].
Lambert FW Jr, Brown JM, Georg LK. Identification of Actinomyces israelii and Actinomyces naeslundii by fluorescent-antibody and agar-gel diffusion techniques. J Bacteriol. Nov 1967;94(5):1287-95. [Medline].
Hall V. Actinomyces--gathering evidence of human colonization and infection. Anaerobe. Feb 2008;14(1):1-7. [Medline].
Karimian F, Feizi S, Nazari R, et al. Delayed-onset Actinomyces keratitis after laser in situ keratomileusis. Cornea. Aug 2008;27(7):843-6. [Medline].
Briscoe D, Edelstein E, Zacharopoulos I, et al. Actinomyces canaliculitis: diagnosis of a masquerading disease. Graefes Arch Clin Exp Ophthalmol. Aug 2004;242(8):682-6. [Medline].
Demant E, Hurwitz JJ. Canaliculitis: review of 12 cases. Can J Ophthalmol. Apr 1980;15(2):73-5. [Medline].
Eloy P, Brandt H, Nollevaux MC, et al. Solid cast-forming actinomycotic canaliculitis: case report. Rhinology. Jun 2004;42(2):103-6. [Medline].
Fulmer NL, Neal JG, Bussard GM, Edlich RF. Lacrimal canaliculitis. Am J Emerg Med. Jul 1999;17(4):385-6. [Medline].
Hussain I, Bonshek RE, Loudon K, et al. Canalicular infection caused by Actinomyces. Eye. 1993;7 (Pt 4):542-4. [Medline].
McKellar MJ, Aburn NS. Cast-forming Actinomyces israelii canaliculitis. Aust N Z J Ophthalmol. Nov 1997;25(4):301-3. [Medline].
Richards WW. Actinomycotic lacrimal canaliculitis. Am J Ophthalmol. Jan 1973;75(1):155-7. [Medline].
Smith RL, Henderson PN. Actinomycotic canaliculitis. Aust J Ophthalmol. Feb 1980;8(1):75-9. [Medline].
Sullivan TJ, Hakin KN, Sathananthan N, et al. Chronic canaliculitis. Aust N Z J Ophthalmol. Nov 1993;21(4):273-4. [Medline].
Takemura M, Yokoi N, Nakamura Y, et al. [Canaliculitis caused by Actinomyces in a case of dry eye with punctal plug occlusion]. Nippon Ganka Gakkai Zasshi. Jul 2002;106(7):416-9. [Medline].
Vécsei VP, Huber-Spitzy V, Arocker-Mettinger E, et al. Canaliculitis: difficulties in diagnosis, differential diagnosis and comparison between conservative and surgical treatment. Ophthalmologica. 1994;208(6):314-7. [Medline].
Marthin JK, Lindegaard J, Prause JU, et al. Lesions of the lacrimal drainage system: a clinicopathological study of 643 biopsy specimens of the lacrimal drainage system in Denmark 1910-1999. Acta Ophthalmol Scand. Feb 2005;83(1):94-9. [Medline].
Perez-Santonja JJ, Campos-Mollo E, Fuentes-Campos E, et al. Actinomyces neuii subspecies anitratus chronic endophthalmitis after cataract surgery. Eur J Ophthalmol. May-Jun 2007;17(3):445-7. [Medline].
Scarano FJ, Ruddat MS, Robinson A. Actinomyces viscosus postoperative endophthalmitis. Diagn Microbiol Infect Dis. Jun 1999;34(2):115-7. [Medline].
Milman T, Mirani N, Gibler T, et al. Actinomyces israelii endogenous endophthalmitis. Br J Ophthalmol. Mar 2008;92(3):427-8. [Medline].
Dhaliwal U, Arora VK, Singh N, et al. Clinical and cytopathologic correlation in chronic inflammations of the orbit and ocular adnexa: a review of 55 cases. Orbit. Dec 2004;23(4):219-25. [Medline].
Leigh RJ, Good EF, Rudy RP. Ophthalmoplegia due to actinomycosis. J Clin Neuroophthalmol. Sep 1986;6(3):157-9. [Medline].
Pagliani L, Campi L, Cavallini GM. Orbital actinomycosis associated with painful ophthalmoplegia. Actinomycosis of the orbit. Ophthalmologica. 2006;220(3):201-5. [Medline].
Sullivan TJ, Aylward GW, Wright JE. Actinomycosis of the orbit. Br J Ophthalmol. Aug 1992;76(8):505-6. [Medline].
Huerva V, Espinet R, Galindo C. Recurrent orbital inflammation and Whipple disease. Ocul Immunol Inflamm. Jan-Feb 2008;16(1):37-9. [Medline].
Stupp T, Pavlidis M, Busse H, et al. Presurgical and postsurgical ultrasound assessment of lacrimal drainage dysfunction. Am J Ophthalmol. Nov 2004;138(5):764-71. [Medline].
Tost F, Bruder R, Clemens S. [20-MHz ultrasound of pre-saccular lacrimal ducts]. Ophthalmologe. Jan 2002;99(1):25-8. [Medline].
Tost F, Bruder R, Clemens S. Clinical diagnosis of chronic canaliculitis by 20-MHz ultrasound. Ophthalmologica. 2000;214(6):433-6. [Medline].
Tost F, Bruder R, Ostendorf M. [High-frequency ultrasonography applied to disorders of the lacrimal canaliculi (Part 2)]. J Fr Ophtalmol. Dec 2003;26(10):1035-8. [Medline].
Barnard D, Davies J, Figdor D. Susceptibility of Actinomyces israelii to antibiotics, sodium hypochlorite and calcium hydroxide. Int Endod J. Sep 1996;29(5):320-6. [Medline].
Martin MV. The use of oral amoxycillin for the treatment of actinomycosis. A clinical and in vitro study. Br Dent J. Apr 7 1984;156(7):252-4. [Medline].
Mohr JA, Rhoades ER, Muchmore HG. Actinomycosis treated with lincomycin. JAMA. Jun 29 1970;212(13):2260-2. [Medline].
Zimmerman TJ, et al, eds. Textbook of Ocular Pharmacology. Philadelphia: Lippincott-Raven; 1997.
Shauly Y, Nachum Z, Gdal-On M, et al. Adjunctive hyperbaric oxygen therapy for actinomycotic lacrimal canaliculitis. Graefes Arch Clin Exp Ophthalmol. Jul 1993;231(7):429-31. [Medline].
Georg LK, Coleman RM, Brown JM. Evaluation of an agar precipitin test for the serodiagnosis of actinomycosis. J Immunol. Jun 1968;100(6):1288-92. [Medline].
Khan A, Lightman S. The eye in gastrointestinal disease. Hosp Med. Sep 2003;64(9):548-51. [Medline].
Lee AG. Ocular whipple's disease. Ophthalmology. Nov 2002;109(11):1952-3; author reply 1953. [Medline].
Medical Economics. Physicians' Desk Reference. NJ: Medical Economics Press; 1999.
Shah JK. Actinomycosis: a ten year review. East Afr Med J. Sep 1971;48(9):496-501. [Medline].
Weinberg RJ, Sartoris MJ, Buerger GF Jr, et al. Fusobacterium in presumed Actinomyces canaliculitis. Am J Ophthalmol. Sep 1977;84(3):371-4. [Medline].
actinomycosis, Actinomycetales, Actinomycetaceae, Actinomycetes, Actinomyces, Actinomyces israelii, A israelii, keratoactinomycosis, keratitis, canaliculitis, anaerobic bacillus, Actinomyces gerencseriae, Actinomyces naeslundii, Actinomyces odontolyticus, Actinomyces viscosus, Actinomyces turicensis, Actinomyces meyeri, Propionibacterium propionicus, Actinobacillus actinomycetemcomitans, Prevotella, Fusobacterium, Bacteroides, Staphylococcus, Streptococcus, Enterobacteriaceae, actinophytosis
Manolette R Roque, MD, MBA, President and CEO, Service Chief of Ocular Immunology and Uveitis, Refractive Surgery, EYE REPUBLIC Ophthalmology Clinic; General Manager, Ophthalmic Consultants Philippines; Section Chief of Ocular Immunology and Uveitis, Department of Ophthalmology, Asian Hospital and Medical Center; Section Chief of Ocular Immunology and Uveitis, Department of Ophthalmology, St. Luke's Medical Center Global City; Senior Eye Surgeon, The LASIK Surgery Clinic
Manolette R Roque, MD, MBA is a member of the following medical societies: American Academy of Ophthalmic Executives, American Academy of Ophthalmology, American Society of Cataract and Refractive Surgery, American Society of Ophthalmic Administrators, American Uveitis Society, International Ocular Inflammation Society, Philippine Medical Association, Philippine Ocular Inflammation Society, and Philippine Society of Cataract and Refractive Surgery
Disclosure: Nothing to disclose.
Barbara L Roque, MD, Full Partner, Ophthalmic Consultants Philippines Co, Chief of Service, Pediatric Ophthalmology and Strabismus, Consulting Staff, Orbit and Eye Plastics, Eye Republic Ophthalmology Clinic
Disclosure: Nothing to disclose.
C Stephen Foster, MD, FACS, FACR, FAAO, Clinical Professor of Ophthalmology, Harvard Medical School; Consulting Staff, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary; Founder and President, Ocular Immunology and Uveitis Foundation, Massachusetts Eye Research and Surgery Institution
C Stephen Foster, MD, FACS, FACR, FAAO is a member of the following medical societies: Alpha Omega Alpha, American Academy of Ophthalmology, American Association of Immunologists, American College of Rheumatology, American College of Surgeons, American Federation for Clinical Research, American Medical Association, American Society for Microbiology, American Uveitis Society, Association for Research in Vision and Ophthalmology, Massachusetts Medical Society, Royal Society of Medicine, and Sigma Xi
Disclosure: Nothing to disclose.
Jorge G Camara, MD, Professor of Ophthalmology, Department of Surgery and Director of Fellowship Training Program in Ophthalmic Plastic and Reconstructive Surgery for Countries Served by the Aloha Medical Mission, University of Hawaii John A Burns School of Medicine
Jorge G Camara, MD is a member of the following medical societies: American Academy of Ophthalmology, American Medical Association, and American Society of Ophthalmic Plastic and Reconstructive Surgery
Disclosure: Nothing to disclose.
Simon K Law, MD, PharmD, Assistant Professor of Ophthalmology, Jules Stein Eye Institute; Chief of Section of Ophthalmology Surgical Services, Department of Veterans Affairs Healthcare Center, West Los Angeles
Simon K Law, MD, PharmD is a member of the following medical societies: American Academy of Ophthalmology, American Glaucoma Society, and Association for Research in Vision and Ophthalmology
Disclosure: Nothing to disclose.
Mark T Duffy, MD, PhD, Consulting Staff, Division of Oculoplastic, Orbito-facial, Lacrimal and Reconstructive Surgery, Green Bay Eye Clinic, BayCare Clinic; Medical Director, Advanced Cosmetic Solutions, A BayCare Clinic
Mark T Duffy, MD, PhD is a member of the following medical societies: American Academy of Ophthalmology, American Medical Association, American Society of Ophthalmic Plastic and Reconstructive Surgery, Sigma Xi, and Society for Neuroscience
Disclosure: Allergan - Botox Cosmetic Consulting fee Consulting; Quest medical - lacrimal balloons Honoraria Speaking and teaching; Ortho-Neutrogenia Consulting fee Consulting
Lance L Brown, OD, MD, Ophthalmologist, Affiliated With Freeman Hospital and St John's Hospital, Regional Eye Center, Joplin, Missouri
Disclosure: Nothing to disclose.
Hampton Roy Sr, MD, Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences
Hampton Roy Sr, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, and Pan-American Association of Ophthalmology
Disclosure: Nothing to disclose.
The authors and editors of eMedicine gratefully acknowledge the assistance of Ryan I Huffman, MD, with the literature review and referencing for this article.
Further ReadingPolenakovik H. Actinomycosis. eMedicine Journal [serial online]. April 14, 2006; Available at: http://www.emedicine.com/Med/topic31.htm.
© 1994-
by Medscape.
All Rights Reserved
(http://www.medscape.com/public/copyright)